These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21063245)

  • 1. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States.
    Blumberg EA; Hauser IA; Stanisic S; Mueller E; Berenson K; Gahlemann CG; Humar A; Jardine AG
    Transplantation; 2010 Dec; 90(12):1420-6. PubMed ID: 21063245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
    Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
    Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.
    Luan FL; Stuckey LJ; Park JM; Kaul D; Cibrik D; Ojo A
    J Am Soc Nephrol; 2009 Nov; 20(11):2449-58. PubMed ID: 19762495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective.
    Kacer M; Kielberger L; Bouda M; Reischig T
    Transpl Infect Dis; 2015 Jun; 17(3):334-41. PubMed ID: 25824586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Low- Versus High-dose Valganciclovir for Prevention of Cytomegalovirus Disease in High-risk Renal Transplant Recipients.
    Gabardi S; Asipenko N; Fleming J; Lor K; McDevitt-Potter L; Mohammed A; Rogers C; Tichy EM; Weng R; Lee RA
    Transplantation; 2015 Jul; 99(7):1499-505. PubMed ID: 25643140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
    Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
    Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS
    Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
    Shiley KT; Gasink LB; Barton TD; Pfeiffenberger P; Olthoff KM; Blumberg EA
    Liver Transpl; 2009 Aug; 15(8):963-7. PubMed ID: 19642123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.
    Luan FL; Kommareddi M; Ojo AO
    Transplantation; 2011 Jan; 91(2):237-44. PubMed ID: 21169881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Cost-Effective Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Gheith O; Halim MA; Al-Otaibi T; Mansour H; Mosaad A; Atteya HA; Zakaria Z; Said T; Nair P; Nampoory N
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):156-163. PubMed ID: 28260458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
    Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.
    Humar A; Limaye AP; Blumberg EA; Hauser IA; Vincenti F; Jardine AG; Abramowicz D; Ives JA; Farhan M; Peeters P
    Transplantation; 2010 Dec; 90(12):1427-31. PubMed ID: 21197713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
    Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation.
    Avidan YP; Paul M; Rahamimov R; Bishara J; Samra Z; Edna S; Mor E
    J Infect; 2008 Sep; 57(3):236-40. PubMed ID: 18674820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanded valganciclovir prophylaxis in kidney transplant recipients is associated with lower incidence of cytomegalovirus infection.
    Večerić-Haler Ž; Bizjak B; Romozi K; Arnol M
    Clin Nephrol; 2017 Supplement 1; 88(13):126-130. PubMed ID: 28601128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.